GlassScriptPhysician profile
Luis M Ayala
NPI 1225367485
$15,435.53
in general payments reported to CMS, 2019-2025
31 companies · $3,533 in 2025
The $3,533 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,036 · 2022: $2,523 · 2023: $3,315 · 2024: $4,028 · 2025: $3,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,299.81 |
| Education | $576.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,558.04 | 2021-2025 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $1,498.31 | 2021-2025 | Tremfya, Stelara, Remicade |
| Dermavant Sciences, INC. | $1,406.87 | 2023-2024 | Vtama |
| Abbvie INC. | $1,352.45 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,246.23 | 2021-2025 | |
| Pfizer INC. | $1,156.96 | 2021-2025 | |
| Genzyme Corporation | $1,024.93 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $961.13 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $875.42 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $668.90 | 2021-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $651.18 | 2022-2025 | Sotyktu |
| Incyte Corporation | $561.15 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $527.53 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Arcutis Biotherapeutics, INC. | $406.89 | 2023-2025 | Zoryve |
| Amgen INC. | $291.86 | 2021-2025 | Otezla, Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $186.46 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $162.17 | 2021 | |
| Blueprint Medicines Corporation | $130.65 | 2025 | |
| Organon LLC | $126.73 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $118.23 | 2021-2025 | Nemluvio |
| Epi Health, LLC | $99.62 | 2021-2022 | |
| Cipher Pharmaceuticals US LLC | $91.53 | 2025 | Spinosad, Natroba |
| Botanix Sb INC | $75.22 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.38 | 2021-2025 | Jublia, Cabtreo |
| Almirall LLC | $46.35 | 2021-2022 | |
| Boston Scientific Corporation | $40.80 | 2021 | |
| Journey Medical Corporation | $24.31 | 2025 | |
| Sandoz INC. | $21.99 | 2021 | |
| Biofrontera INC. | $20.83 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Dermira, INC. | $18.43 | 2021 | |
| Verrica Pharmaceuticals INC. | $15.98 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.